Scandion Oncology A/S is a listed Danish biotechnology company with the mission to address one of the most important challenges in modern oncology - the effective treatment of cancer which has developed resistance towards existing cancer medicine. The company's first-in-class lead compound, SCO-101, is an add-on to chemotherapy and is currently in clinical phase I and II studies in cancer patients. The company also has several preclinical programs to build a broader pipeline of drugs for the treatment of drug resistant cancer diseases.